RYTM News and Press, Rhythm Pharmaceuticals Inc. From 03/30/20

 Hunter Smith, Chief Financial Officer, appointed Interim Chief Executive Officer following completion of NDA submission to FDA    Precautionary measures in place to mitigate impact of COVID-19 on clinical programs  BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhyt...

BOSTON, March 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that it has completed its rolling submissi...

BOSTON, March 18, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration...

BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Murray Stewart, M.D., Chief Medical Of...

NuVasive (NASDAQ: NUVA ) initiated with Buy rating and $93 (19% upside) price target at SunTrust. More news on: NuVasive, Inc., OrthoPediatrics Corp., PerkinElmer, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Keith Gottesdiener, M.D. to Step Down as Chief Executive Officer Following NDA Submission for Setmelanotide in POMC and LEPR Deficiency Obesities Expected in the First Quarter of 2020 Board Forms Search Committee to Assist in Identifying Successor BOSTON, Jan. 06, 2020 (GLOBE NEWS...

Rhythm Pharmaceuticals ( RYTM +4.3% ) is up on below-average volume in response to its announcement that enrollment has been completed in a Phase 3 clinical trial evaluating setmelanotide in Bardet-Biedl and Alström syndrome patients who are moderately or severely obese....

-- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand -- BOSTON, Dec. 05, 2019 (GLOBE NEWSWIRE) --  Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical com...

BOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Chief Financial Officer of Rhythm, w...

Investment thesis: Reduced treatable patient population, lack of placebo and numerous side effects will tank RYTM Diseases with a common genetic origin can be addressed with a single bullet drug or gene-therapy. Rhythm Pharmaceuticals ( RYTM ) is instead applying a “hammer”...